Cochrane · systematic review · CD015245
Intratympanic corticosteroids for Ménière’s disease
Webster, KE, Lee, A, Galbraith, K, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
ENTAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 57.1%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intratympanic corticosteroids compared to placebo/no treatment for Ménière’s disease
Population: adults with Ménière’s disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in vertigo frequency Intratympanic corticosteroids vs placebo/no treatment | RR 1 [0.92, 1.1] | 2 studies · 60 participants | Low Downgraded: risk of bias, imprecision |
Improvement in vertigo frequency Intratympanic corticosteroids vs placebo/no treatment | RR 1.03 [0.87, 1.23] | 2 studies · 58 participants | Low Downgraded: risk of bias, imprecision |
Change in vertigo (global score) Intratympanic corticosteroids vs placebo/no treatment | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias, imprecision |
Change in vertigo (frequency) Intratympanic corticosteroids vs placebo/no treatment | no estimate extracted | 3 studies · 472 participants | Low Downgraded: risk of bias, imprecision |
Change in vertigo (frequency) Intratympanic corticosteroids vs placebo/no treatment | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Change in vertigo (frequency) Intratympanic corticosteroids vs placebo/no treatment | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Intratympanic corticosteroids vs placebo/no treatment | RR 0.64 [0.22, 1.85] | 4 studies · 500 participants | Very low Downgraded: risk of bias, imprecision |